We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
+21.02%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$161M
AUM Growth
-$8.98M
Cap. Flow
-$4.31M
Cap. Flow %
-2.68%
Top 10 Hldgs %
86.68%
Holding
32
New
3
Increased
7
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
EPIX
ESSA Pharma
EPIX
+$13.4M
2
IMA
ImageneBio Inc
IMA
+$4.82M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$3.18M
4
PMVP icon
PMV Pharmaceuticals
PMVP
+$2.82M
5
TIL icon
Instil Bio
TIL
+$1.98M

Top Sells

Rank Stock Value
1
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$16.1M
2
TECX
Tectonic Therapeutic
TECX
+$6.42M
3
OKUR
OnKure Therapeutics
OKUR
+$5.88M
4
LENZ
LENZ Therapeutics
LENZ
+$1.55M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$1.07M

Sector Composition

Rank Sector Weight
1 Healthcare 82.88%
2 Technology 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$793M
$35.3M 21.95%
14,250,000
– –
SGOV icon
2
iShares 0-3 Month Treasury Bond ETF
SGOV
$97.5B
$26.1M 16.2%
260,000
-10,000
-4% -$1M
AVIR icon
3
Atea Pharmaceuticals
AVIR
$390M
$25.5M 15.83%
7,608,312
+958,312
+14% +$3.18M
ADVM
4
DELISTED
Adverum Biotechnologies
ADVM
$10.6M 6.58%
2,268,064
– –
ANTX icon
5
AN2 Therapeutics
ANTX
$169M
$7.93M 4.93%
5,749,432
– –
TIL icon
6
Instil Bio
TIL
$50.3M
$7.64M 4.74%
400,000
+65,000
+19% +$1.98M
EPIX
7
DELISTED
ESSA Pharma
EPIX
$7.56M 4.69%
+4,221,546
New +$13.4M
WHWK
8
Whitehawk Therapeutics
WHWK
$192M
$6.63M 4.12%
2,100,000
+100,000
+5% +$227K
ORMP icon
9
Oramed Pharmaceuticals
ORMP
$165M
$6.4M 3.97%
2,643,907
+457,716
+21% +$1.09M
IMA
10
ImageneBio Inc
IMA
$60.7M
$5.88M 3.65%
298,822
+238,548
+396% +$4.82M
PMVP icon
11
PMV Pharmaceuticals
PMVP
$71.5M
$5.23M 3.25%
3,466,684
+1,777,912
+105% +$2.82M
ACHL
12
DELISTED
Achilles Therapeutics
ACHL
$4.67M 2.9%
4,100,002
– –
CNTB
13
Connect Biopharma Holdings
CNTB
$150M
$2.89M 1.79%
2,093,232
– –
MIST icon
14
Milestone Pharmaceuticals
MIST
$148M
$2.68M 1.67%
1,136,091
– –
LONA
15
LeonaBio Inc
LONA
$67.8M
$1.63M 1.01%
+277,589
New +$1.57M
ASTC icon
16
Astrotech Corp
ASTC
$15.5M
$1.48M 0.92%
220,410
– –
LSTA icon
17
Lisata Therapeutics
LSTA
$32.8M
$848K 0.53%
284,669
– –
PVLA
18
Palvella Therapeutics
PVLA
$2.26B
$506K 0.31%
42,130
– –
VTGN icon
19
VistaGen Therapeutics
VTGN
$9.4M
$443K 0.27%
150,000
– –
KZR
20
DELISTED
Kezar Life Sciences
KZR
$327K 0.2%
+48,668
New +$363K
LENZ
21
LENZ Therapeutics
LENZ
$162M
$268K 0.17%
9,271
-50,729
-85% -$1.55M
NXTC icon
22
NextCure
NXTC
$24.4M
$211K 0.13%
22,795
-244
-1% -$3.59K
VRCA icon
23
Verrica Pharmaceuticals
VRCA
$96M
$122K 0.08%
17,465
-535
-3% -$5.88K
KLRS
24
Kalaris Therapeutics
KLRS
$104M
$77.4K 0.05%
8,011
-18,210
-69% -$275K
HLVX
25
DELISTED
HilleVax
HLVX
$43K 0.03%
20,760
+1,000
+5% +$1.88K
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
TI
Truxt Investmentos Rio De Janeiro, Brazil $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
IWA
Invera Wealth Advisors Bend, Oregon $156M AUM 22.76% 1-Year Est. Return
PFO
Pioneer Family Office North Miami Beach, Florida $156M AUM
HCWM
Hidden Cove Wealth Management Bainbridge Island, Washington $156M AUM 16.51% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return

BML Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, BML Capital Management held 32 positions worth $161M, down 5.3% from $170M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

BML Capital Management's Q4 2024 filing shows 3 new, 7 increased, 5 reduced and 7 closed positions. Its largest new stake was ESSA Pharma: 4,221,546 shares worth $7.56M. The largest sale was State Street SPDR Bloomberg 1-3 Month T-Bill ETF, an estimated $16.1M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 74% a quarter earlier, followed by Technology.

  • BML Capital Management's largest Q4 2024 buy was ESSA Pharma: 4,221,546 shares worth $7.56M.
  • BML Capital Management added most to ImageneBio Inc in Q4 2024, an estimated $4.82M increase.
  • BML Capital Management's biggest Q4 2024 reduction was LENZ Therapeutics, cutting an estimated $1.55M.
  • BML Capital Management fully exited State Street SPDR Bloomberg 1-3 Month T-Bill ETF in Q4 2024, selling an estimated $16.1M.
  • BML Capital Management's ten largest holdings make up 87% of its $161M portfolio in Q4 2024.
  • BML Capital Management opened 3 new positions and closed 7 in Q4 2024.
  • BML Capital Management's portfolio value fell 5.3% quarter-over-quarter to $161M.

Based on BML Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.